Astellas Gene Therapies

Astellas Gene Therapies Summary

Company Summary

Astellas Gene Therapies (formerly known as Audentes Therapeutics) is a biotechnology company committed to the development and commercialization of innovative new treatments for patients with serious, rare diseases through the application of gene therapy technology. The Company currently has four programs in development: AT132 for the treatment of X-Linked Myotubular Myopathy, an ultra-rare, severe, debilitating disease that affects skeletal muscles. AT342 for the treatment of Crigler-Najjar Syndrome, a rare, congenital autosomal recessive monogenic disease characterized by severely high levels of bilirubin in the blood and risk of irreversible neurological damage and death. AT307 for the treatment of CASQ2-related Catecholaminergic Polymorphic Ventricular Tachycardia, an inherited disease characterized by abnormal ventricular heartbeats. AT982 for the treatment of Pompe disease, a rare, inherited disorder characterized by progressive muscle weakness and respiratory impairment.
San Francisco, CA, US | view all locations
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data

Key People

  • Amy Pott

    Amy Pott, Division Head of Gene Therapy Commercial

    • Andy Krivoshik

      Andy Krivoshik, President and Head of Development

    • Richard Wilson

      Richard Wilson, Senior Vice President, Primary Focus Lead, Genetic Regulation

    • Jason Schwartz

      Jason Schwartz, VP, Medical Affairs

    LocationsView all

    1 location detected

    • San Francisco, CA HQ

      United States

      600 California St 17th Floor, San Francisco

    Astellas Gene Therapies Financials

    Summary Financials

    Net income (Q3, 2019)
    Cash (Q3, 2019)
    EBIT (Q3, 2019)

    Footer menu